HBV Treatment Decision-Making
Premiere Date: Tuesday, December 15, 2020This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, December 15, 2021
Note: Credit Is No Longer Available
 | Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD, Director, Liver Institute Northwest Clinical Professor, Elson S. Floyd College of Medicine Washington State University Seattle, WA |
 | Paul Y. Kwo, MD Professor of Medicine Director of Hepatology Stanford University School of Medicine Stanford, CA |
Chronic hepatitis B virus (HBV) is a serious public health concern that is often underrated despite the approval of newer therapies and subsequent updated guidelines. Integrating guideline-directed treatment can reduce the morbidity and mortality associated with HBV.
In this second episode of the four-part CMEOCast Podcast to Practice series "Meeting Patients Where They Live: Community-Based Efforts to Improve Screening and Treatment of HBV," faculty experts will discuss the efficacy and safety profiles of current agents for HBV, guiding clinicians through best practices when initiating or switching treatment. In addition, while there is currently no cure for HBV, considering the promise for the future, faculty experts will define "functional cure" for HBV and its application to agents in development.
At the end of this CE activity, participants should be able to:
- Optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV
- Define functional cure for HBV and how it applies to HBV agents in development.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize how to optimize efficacy and safety profiles of current agents when initiating or switching treatment for patients with HBV
- Define functional cure for HBV and how it applies to HBV agents in development.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, OB/GYNs, emergency department physicians, PAs, nurse practitioners, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.75 contact hours (0.075 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-168-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format:
Enduring activity
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.cmeoutfitters.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.
Dr. Kwo reports that he receives grants from Assembly Biosciences, Inc.; Bristol-Myers Squibb; and Gilead Sciences, Inc. He is on the advisory committee for Aligos Therapeutics, Inc. and Gilead Sciences, Inc. He receives other financial or material support as a Data and Safety Monitoring Board (DSMB) member for Janssen Pharmaceuticals, Inc.
Kashemi Rorie, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-036-121520-47
